Abstract
Intracellular degradation of proteins constitutes a vital regulatory switch in a variety of central cellular processes. Additionally, it provides an essential mechanism in protein turnover for amino acid regeneration. Several mechanisms of protein degradation are known, but the majority of regulatory proteins are degraded through the ubiquitin-proteasome pathway. This pathway has thus been implicated in the control of apoptosis, cell cycle progression, immune response, development, transcriptional regulation, signal transduction, and receptor down-regulation. The complex nature of this, and other proteolysis mechanisms, and their critical roles in cellular processes underlies the existence of many aberrations related to several pathogenic diseases, both acquired and inherited. In this chapter, two major mechanisms of protein degradation, the ubiquitin proteasome system and the lysosome, will be discussed in relation to diseases resulting from mutations in a particular step of the pathways, and from mutations in proteins that induce their stabilization or degradation (summarized in Table 1).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Accili D, Kadowaki T, Kadowaki H, Mosthaf L, Ullrich A, Taylor SI (1992) Immunoglobulin heavy chain-binding protein binds to misfolded mutant insulin receptors with mutations in the extracellular domain. J Biol Chem 267:586–590
Angelman H (1965) Puppet children: a report of three cases. Dev Med Child Neurol 7:681–688
Bass J, Turck C, Rouard M, Steiner DF (2000) Furin-mediated processing in the early secretory pathway: sequential cleavage and degradation of misfolded insulin receptors. Proc Nati Acad Sci USA 97:11905–11909
Bauskin AR, Zhang HP, Fairlie WD, He XY, Russell PK, Moore AG, Brown DA, Stanley KK, Breit SN (2000) The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-beta super-family member, acts as a quality control determinant for correctly folded MIC-1. EMBO J 19:2212–2220
Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM (1999) Degradation of alpha-synuclein by proteasome. J Biol Chem 274:33855–33858
Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS (1996) Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abetal-42/1-40 ratio in vitro and in vivo. Neuron 17:1005–1013
Braulke T (1996) Biology of the lysosome. In: Lloyd JB, Mason RW (eds) Subcellular biochemistry, vol 27. Plenum, New York, pp 15–40.
Bush KT, Goldberg AL, Nigam SK (1997) Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J Biol Chem 272: 9086–9092
Ciechanover A (1998) The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17:7151–7160
Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ (1997) Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3:67–72
Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733–25741
Cole NB, Ellenberg J, Song J, DiEuliis D, Lippincott-Schwartz J (1998) Retrograde transport of Golgi-localized proteins to the ER. J Cell Biol 140:1–15
Cooper KF, Mallory MJ, Smith JB, Strich R (1997) Stress and developmental regulation of the yeast C-type cyclin Ume3p (Srb11p/Ssn8p). EMBO J 16:4665–4675
Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein mis-folding in SCA1. Nat Genet 19:148–154
Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537–548
DebBurman SK, Raymond GJ, Caughey B, Lindquist S (1997) Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Nati Acad Sci USA 94:13938–13943
Deshaies RJ (1999) SCF and Cullin/RING H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 15:435–467
Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710–713
Ebina Y, Ellis L, Jarnagin K, Edery M, Graf L, Clauser E, Ou JH, Masiarz F, Kan YW, Goldfine ID et al. (1985) The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 40:747–758
Ellgaard L, Molinari M, Helenius A (1999) Setting the standards: quality control in the secretory pathway. Science 286:1882–1888
Freemont PS (2000) RING for destruction.? Curr Biol 10:R84–R87
Gasset M, Baldwin MA, Lloyd DH, Gabriel JM, Holtzman DM, Cohen F, Fletterick R, Prusiner SB, Sanjay TW (1992) Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. Proc Nati Acad Sci USA 89:10940–10944
Gaut JR, Hendershot LM (1993) The modification and assembly of proteins in the endoplasmic reticulum. Curr Opin Cell Biol 5:589–595
Gieselmann V (1995) Lysosomal storage diseases. Biochim Biophys Acta 1270:103–136
Glickman MH, Rubin DM, Coux O, Wefes I, Pfeifer G, Cjeka Z, Baumeister W, Fried VA, Finley D, Sanjay TW (1998) A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 94:615–623
Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R (1997) Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386:463–471
Harris DA (1999) Cellular biology of prion diseases. Clin Microbiol Rev 12:429–444
Hartl FU (1996) Molecular chaperones in cellular protein folding. Nature 381:571–579
Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT (1989) HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905–3910
Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, Lingappa VR (1998) A transmembrane form of the prion protein in neurodegenerative disease. Science 279:827–834
Hendrick JP, Hartl FU (1993) Molecular chaperone functions of heat-shock proteins. Annu Rev Biochem 62:349–384
Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479
Hiller MM, Finger A, Schweiger M, Wolf DH (1996) ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway. Science 273:1725–1728
Hilt W, Wolf DH (1996) Proteasomes: destruction as a programme. Trends Biochem Sci 21: 96–102
Huibregtse JM, Scheffner M, Beaudenon S, Howley PM (1995) A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Nati Acad Sci USA 92:2563–2567
Imamura T, Haruta T, Takata Y, Usui I, Iwata M, Ishihara H, Ishiki M, Ishibashi O, Ueno E, Sasaoka T, Kobayashi M (1998) Involvement of heat shock protein 90 in the degradation of mutant insulin receptors by the proteasome. J Biol Chem 273:11183–11188
Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83:129–135
Jin T, Gu Y, Zanusso G, Sy M, Kumar A, Cohen M, Gambetti P, Singh N (2000) The chaperone protein BiP binds to a mutant prion protein and mediates its degradation by the proteasome. J Biol Chem 275:38699–38704
Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC (1999) The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286: 309–312
Joazeiro CA, Weissman AM (2000) RING finger proteins: mediators of ubiquitin ligase activity. Cell 102:549–552
Johnson PR, Swanson R, Rakhilina L, Hochstrasser M (1998) Degradation signal masking by heterodimerization of MATalpha2 and MATal blocks their mutual destruction by the ubiquitin-proteasome pathway. Cell 94:217–227
Kadowaki H, Kadowaki T, Cama A, Marcus-Samuels B, Rovira A, Bevins CL, Taylor SI (1990) Muta-genesis of lysine 460 in the human insulin receptor. Effects upon receptor recycling and cooperative interactions among binding sites. J Biol Chem 265:21285–21296
Kamp W, Berk MB, Visser CJ, Nottet HS (2000) Mechanisms of HIV-1 to escape from the host immune surveillance. Eur J Clin Invest 30:740–746
Kerkau T, Bacik I, Bennink JR, Yewdell JW, Hunig T, Schimpl A, Schubert U (1997) The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med 185: 1295–1305
Kim JN, Shadlen MN (1999) Neural correlates of a decision in the dorsolateral prefrontal cortex of the macaque. Nat Neurosci 2:176–185
Kim TW, Pettingell WH, Hallmark OG, Moir RD, Wasco W, Tanzi RE (1997) Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J Biol Chem 272:11006–11010
Kishino T, Lalande M, Wagstaff J (1997) UBE3A/E6-AP mutations cause Angelman’s syndrome. Nat Genet 15:70–73
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkin-sonism. Nature 392:605–608
Kornitzer D, Raboy B, Kulka RG, Fink GR (1994) Regulated degradation of the transcription factor Gcn4. EMBO J 13:6021–6030
Kruger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 18:106–108
Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, Mayer RJ, Layfield R (2000) Inhibition of the ubiquitin-proteasome system in Alzheimer’s disease. Proc Nati Acad Sci USA 97:9902–9906
Larsen CN, Krantz BA, Wilkinson KD (1998) Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37:3358–3368
Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320
Le Gall S, Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L, Benarous R, Heard JM, Schwartz O (1998) Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 8:483–495
Lee DH, Goldberg AL (1998) Proteasome inhibitors cause induction of heat shock proteins and trehalose, which together confer thermotolerance in Saccharomyces cerevisiae. Mol Cell Biol 18:30–38
Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH, Sanjay TW (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395:451–452
Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685–688
Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG (1997) Inhibition of ubiquitin/ proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Nati Acad Sci USA 94:12616–12621
Liddle G, Bledsoe T, Coppage WS Jr (1963) A familial renal disorder simulating primary aldos-teronism but with negligible aldosterone secretion. Trans Assoc Am Phys 76:199–213
Lloyd JB, Mason RW (1996) Biology of the lysosome. Plenum Press, New York
Loda M, Cukor B, Tarn SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231–234
Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V, Thomas D, Strebel K, Benarous R (1998) A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1:565–574
Martin JB (1999) Molecular basis of the neurodegenerative disorders. N Engl J Med 340 1970–198.
Masucci MG, Ernberg I (1994) Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol 2:125–130
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Mäher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275
Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254
Mizuno Y, Hattori N, Matsumine H (1998) Neurochemical and neurogenetic correlates of Parkinson’s disease. J Neurochem 71:893–902
Pagano M (1997) Cell cycle regulation by the ubiquitin pathway. FASEB J 11:1067–1075
Payne AS, Kelly EJ, Gitlin JD (1998) Functional expression of the Wilson disease protein reveals mislocalization and impaired copper-dependent trafficking of the common H1069Q mutation Proc Nati Acad Sci USA 95:10854–10859
Perutz MF, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Nati Acad Sci USA 91:5355–5358
Plemper RK, Wolf DH (1999) Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem Sci 24:266–270
Plemper RK, Boehmler S, Bordallo J, Sommer T, Wolf DH (1997) Mutant analysis links the translocon and BiP to retrograde protein transport for ER degradation. Nature 388:891–895
Ploegh HL (1998) Viral strategies of immune evasion. Science 280:248–253
Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer’s disease and transgenic models. Annu Rev Neurosci 21:479–505
Prusiner SB (1997) Prion diseases and the BSE crisis. Science 278:245–251
Prusiner SB (1998) Prions. Proc Nati Acad Sci USA 95:13363–13383
Prusiner SB, Scott MR, DeArmond SJ, Cohen FE (1998) Prion protein biology. Cell 93:337–348
Qu D, Teckman JH, Omura S, Perlmutter DH (1996) Degradation of a mutant secretory protein, alpha 1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem 271:22791–22795
Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761–771
Rubin DM, Glickman MH, Larsen CN, Dhruvakumar S, Finley D (1998) Active site mutants in the six regulatory particle ATPases reveal multiple roles for ATP in the proteasome. EMBO J 17:4909–4919
Sawa T, Imamura T, Haruta T, Sasaoka T, Ishiki M, Takata Y, Takada Y, Morioka H, Ishihara H, Usui I, Kobayashi M (1996) Hsp70 family molecular chaperones and mutant insulin receptor: differential binding specificities of BiP and Hsp70/Hsc70 determines accumulation or degradation of insulin receptor. Biochem Biophys Res Commun 218:449–453
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495–505
Schellenberg GD (1995) Genetic dissection of Alzheimer’s disease, a heterogeneous disorder. Proc Nati Acad Sci USA 92:8552–8559
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2:864–870
Schirmer EC, Lindquist S (1997) Interactions of the chaperone Hsp104 with yeast Sup35 and mammalian PrP. Proc Nati Acad Sci USA 94:13932–13937
Schwartz O, Maréchal V, Le Gall S, Lemonnier F, Heard JM (1996) Endocytosis of major histo-compatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2:338–342
Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302–305
Skinner PJ, Koshy BT, Cummings CJ, Klement IA, Helin K, Servadio A, Zoghbi HY, Orr HT (1997) Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 389:971–974
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840
Staub O, Gautschi I, Ishikawa T, Breitschopf K, Ciechanover A, Schild L, Rotin D (1997) Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination. EMBO J 16:6325–6336
Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393:229–234
Stott K, Blackburn JM, Butler PJ, Perutz M (1995) Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative diseases. Proc Nati Acad Sci USA 92:6509–6513
Tanzi RE, Kovacs DM, Kim TW, Moir RD, Guenette SY, Wasco W (1996) The gene defects responsible for familial Alzheimer’s disease. Neurobiol Dis 3:159–168
Taylor SI (1992) Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 41:1473–1490
Treier M, Staszewski LM, Bohmann D (1994) Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78:787–798
Tyers M, Jorgensen P (2000) Proteolysis and the cell cycle: with this RING I do thee destroy. Curr Opin Genet Dev 10:54–64
van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, Koycu S, Ramdjielal RDJ, Salehi A, Martens GJM, Grosveld FG, Peter J, Burbach H, Hoi EM (1998) Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer’s and Down patients. Science 279:242–247
Varshavsky A (1996) The N-end rule: functions, mysteries, uses. Proc Nati Acad Sci USA 93:12142–12149
Voges D, Zwickl P, Baumeister W (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68:1015–1068
Ward CL, Omura S, Kopito RR (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83:121–127
Weissmann C (1999) Molecular genetics of transmissible spongiform encephalopathies. J Biol Chem 274:3–6
Welch WJ, Gambetti P (1998) Chaperoning brain diseases. Nature 392:23–24
Werner ED, Brodsky JL, McCracken AA (1996) Proteasome-dependent endoplasmic reticulum-associated protein degradation: an unconventional route to a familiar fate. Proc Nati Acad Sci USA 93:13797–13801
Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR, Rapoport TA, Ploegh HL (1996) Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384:432–438
Willey RL, Maldarelli F, Martin MA, Strebel K (1992) Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 66:7193–7200
Winchester B, Vellodi A, Young E (2000) The molecular basis of lysosomal storage diseases and their treatment. Biochem Soc Trans 28:150–154
Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH (1994) A lag in intra-cellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Nati Acad Sci USA 91:9014–9018
Yaglom J, Linskens MH, Sadis S, Rubin DM, Futcher B, Finley D (1995) p34Cdc28-mediated control of Cln3 cyclin degradation. Mol Cell Biol 15:731–741
Yost CS, Lopez CD, Prusiner SB, Myers RM, Lingappa VR (1990) Non-hydrophobic extracyto-plasmic determinant of stop transfer in the prion protein. Nature 343:669–672
Zanusso G, Petersen RB, Jin T, Jing Y, Kanoush R, Ferrari S, Gambetti P, Singh N (1999) Protea-somal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem 274:23396–23404
Zhang S, Rich A (1997) Direct conversion of an oligopeptide from a beta-sheet to an alpha-helix: a model for amyloid formation. Proc Nati Acad Sci USA 94:23–28
Zhou M, Wu X, Ginsberg HN (1996) Evidence that a rapidly turning over protein, normally degraded by proteasomes, regulates hsp72 gene transcription in HepG2 cells. J Biol Chem 271:24769–24775
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Plemper, R.K., Hammond, A.L. (2002). Protein Degradation in Human Disease. In: Reboud-Ravaux, M. (eds) Protein Degradation in Health and Disease. Progress in Molecular and Subcellular Biology, vol 29. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56373-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-56373-7_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62714-9
Online ISBN: 978-3-642-56373-7
eBook Packages: Springer Book Archive